Eli Lilly’s evaluation of Peptron’s SmartDepot long-acting injectable platform remains active following the December 2025 extension of their original 14-month agreement through the October 7, 2026 deadline. Trader sentiment for a full commercial license by that date sits in a near-even split because Lilly continues to prioritize oral GLP-1 candidates such as orforglipron, shifting resources away from injectable delivery enhancements. The PLGA-based microsphere technology has demonstrated potential for monthly dosing of peptide drugs, yet no binding technology-transfer terms have been disclosed despite ongoing joint research. Key swing factors include the final evaluation readout expected in the coming months and any Lilly statements on manufacturing scale-up or auto-injector integration that could tip the market decisively toward “Yes.”
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日新規
新規
2026/10/07
新規
新規
2026/10/07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s evaluation of Peptron’s SmartDepot long-acting injectable platform remains active following the December 2025 extension of their original 14-month agreement through the October 7, 2026 deadline. Trader sentiment for a full commercial license by that date sits in a near-even split because Lilly continues to prioritize oral GLP-1 candidates such as orforglipron, shifting resources away from injectable delivery enhancements. The PLGA-based microsphere technology has demonstrated potential for monthly dosing of peptide drugs, yet no binding technology-transfer terms have been disclosed despite ongoing joint research. Key swing factors include the final evaluation readout expected in the coming months and any Lilly statements on manufacturing scale-up or auto-injector integration that could tip the market decisively toward “Yes.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
マーケット開始日： May 5, 2026, 8:02 PM ET
音量
$8,217終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s evaluation of Peptron’s SmartDepot long-acting injectable platform remains active following the December 2025 extension of their original 14-month agreement through the October 7, 2026 deadline. Trader sentiment for a full commercial license by that date sits in a near-even split because Lilly continues to prioritize oral GLP-1 candidates such as orforglipron, shifting resources away from injectable delivery enhancements. The PLGA-based microsphere technology has demonstrated potential for monthly dosing of peptide drugs, yet no binding technology-transfer terms have been disclosed despite ongoing joint research. Key swing factors include the final evaluation readout expected in the coming months and any Lilly statements on manufacturing scale-up or auto-injector integration that could tip the market decisively toward “Yes.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$8,217終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s evaluation of Peptron’s SmartDepot long-acting injectable platform remains active following the December 2025 extension of their original 14-month agreement through the October 7, 2026 deadline. Trader sentiment for a full commercial license by that date sits in a near-even split because Lilly continues to prioritize oral GLP-1 candidates such as orforglipron, shifting resources away from injectable delivery enhancements. The PLGA-based microsphere technology has demonstrated potential for monthly dosing of peptide drugs, yet no binding technology-transfer terms have been disclosed despite ongoing joint research. Key swing factors include the final evaluation readout expected in the coming months and any Lilly statements on manufacturing scale-up or auto-injector integration that could tip the market decisively toward “Yes.”
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問